THOUGHT LEADERSHIP

 

China’s NGS Market – Maturing for NIPT & Promising for Oncology

Mar 01, 2018

Since 2014, the Chinese government started to regulate NGS (Next Generation Sequencing) market for clinical applications and NGS technology has been more and more adopted especially for NIPT (Non-Invasive Prenatal Test) and cancer diagnosis and treatment. There are many topics can be talked in this market and SmithStreet would like to share the following 3 points: (for more specific market insights, please send a request to info@smithstreetsolutions.com)  

1.  ICLs (Independent Commercial Labs) are leading NGS technology and keep growing
SmithStreet updated China’s ICL list to the end of 2017. Number of new ICLs keeps growing from 2016 to 2017 with more individual labs focusing on gene sequencing technologies, yet an integration is already seen in the ICL market and large ICL chains will expand their dominance.


Exhibit 1: There are more than 1,000 ICLs in China and ~50% of them are located in Beijing, Shanghai and eastern coastal provinces –  Guangdong, Jiangsu, Zhejiang, Shandong



Exhibit 2: ICL market has been booming since 2015 and more newly established ICLs are focused on “Precision Medicine”


2.  NIPT segment is maturing and experiencing a volume shift from ICLs to prenatal diagnosis centers
After “Two-child Policy” went into effect in January 2016, NIPT needs have increased due to increasing number of pregnant women above 35 years old with relatively high risks. In October 2016, NIPT standards were released to emphasize the key role of Prenatal Diagnosis Center Hospitals. It is seen a testing volume shift from commercial labs to the hospitals, which drives more cooperation between hospitals and ICLs in NGS instrument/reagents and techniques improvement.


Link: National Health and Family Planning Commission’s No.45 Document to announce NIPT Standards

http://www.nhfpc.gov.cn/fys/s3581/201611/0e6fe5bac1664ebda8bc28ad0ed68389.shtml


3.  Cancer segment is promising and attracting capital investment, but this segment is still under uncertain factors such as technology development and regulatory issues 
Currently, main use for NGS in cancer is companion diagnostics for targeted therapy. A wider and more mature use still needs clinical data accumulation, technology breakthrough, CFDA approval and relevant standards release. Capital market in NGS for cancer research and clinical application is highly active in China due to the huge market potential.


Free Lunch is a bite size dose of China content to help keep you up to date on trends and happenings in the China market.

SmithStreet will be providing you free content we think will be valuable to you and your organization. Please feel free to drop us a note at info@smithstreetsolutions.com if you have topics of interest you would like us to cover or any questions about the China market.


About the Author

Connect with SmithStreet
In the News

Technology|Jun 14, 2017

Programmatic Advertising in China

Consumer Goods|May 22, 2017

China Will Allow U.S. Beef Imports

Luxury|May 11, 2017

China's Return to Great Retail Service

Reuters|Nov 18, 2016

New Look Seeks Fashion Edge in China with Local Designs

Bloomberg|Jul 18, 2016

Nestle Seeks China Turnaround Online as Competitors Abound

LoginNot a registered user? Register now.
E-mail
Password
Remember me

Login using your social network

RegisterAlready registered? Login now.

SmithStreet provides you source for today’s leading business ideas. Our content explores the topics critical to China market today.

Create your SmithStreet account:

E-mail address & password

*E-mail
Make sure you typed it correctly.
*Password
Make it 6-10 characters, no spaces
*Confirm Password

Personal Information

*First Name
*Last Name
Company
Job Title
Job Function
Country
Screen Name

Subscribe

Subscribe to our China Spotlight weekly news feed - a complimentary email newsletter that matters to your China strategy.

Healthcare

Consumers and Retail

I agree with the Legal Terms.
RegisterAlready registered?

Create your SmithStreet account:

*E-mail
Make sure you typed it correctly.
*Password
Make it 6-10 characters, no spaces
*Confirm Password

Personal Information

*First Name
*Last Name
Company
Job Title
Job Function
Country
Screen Name
Legal Terms
This is the official privacy policy for www.smithstreetchina.com, which is administered, owned and operated by SmithStreet. This policy is intended to provide you with important information regarding your use of the Site.

This Site is owned, operated and targeted for use in China and may not comply with other nation’s laws or regulations. Your continued use of this Site implies your acceptance of our policies and practices as described below.

We do not collect any personally identifiable information from visitors to the site unless they voluntarily submit information.

You may choose to subscribe to our email edition, which requires you to submit a valid email address. This service is operated for free on an opt-in basis, and you may unsubscribe at any time by emailing info@smithstreetsolutions.com.

The information we collect is used for internal review and is then discarded, used to improve the content of our website page.

We do not set any cookies.

If you do not want to receive e-mail from us in the future, please let us know by sending us e-mail at the above address.

All of the content posted on our Site is created in-house. We do summarize news from other resources by following fair convention. If, for any reason, you would like us to remove any content, graphics, or other information that you consider a breach of copyright law, please email us, or feel free to call us by below number.

We reserve the right to revise this policy at any time. Revisions will be posted in this location. Any and all posted revisions are effective immediately. Please check back often to stay informed about your use of the Site.

Please contact us directly if you have any questions about this Policy or anything else.

Email: info@smithstreetsolutions.com
Tel: (8621) 6565 6533

This Policy was last modified on November 1st, 2013 and is effective immediately.